Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Barry P. Davis"'
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
PurposeThis study aimed to determine the 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drug use.MethodsThis is a post-trial passive follow-up study of Antihypertensive and Lipi
Externí odkaz:
https://doaj.org/article/4976e1bc27654f699c01291dc165f61b
Autor:
Lisa J. Woodhouse, Alan A. Montgomery, Jonathan Mant, Barry R. Davis, Ale Algra, Jean-Louis Mas, Jan A. Staessen, Lutgarde Thijs, Andrew Tonkin, Adrienne Kirby, Stuart J. Pocock, John Chalmers, Graeme J. Hankey, J. David Spence, Peter Sandercock, Hans-Christoph Diener, Shinichiro Uchiyama, Nikola Sprigg, Philip M. Bath
Publikováno v:
BMC Medical Research Methodology, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Vascular prevention trials typically use dichotomous event outcomes although this may be inefficient statistically and gives no indication of event severity. We assessed whether ordinal outcomes would be more efficient and how to
Externí odkaz:
https://doaj.org/article/bc8e91c4778843a2ac8746e7d42965c2
Autor:
Ana-Catarina Pinho-Gomes, Luis Azevedo, Emma Copland, Dexter Canoy, Milad Nazarzadeh, Rema Ramakrishnan, Eivind Berge, Johan Sundström, Dipak Kotecha, Mark Woodward, Koon Teo, Barry R Davis, John Chalmers, Carl J Pepine, Kazem Rahimi, Blood Pressure Lowering Treatment Trialists’ Collaboration
Publikováno v:
PLoS Medicine, Vol 18, Iss 6, p e1003599 (2021)
BackgroundRandomised evidence on the efficacy of blood pressure (BP)-lowering treatment to reduce cardiovascular risk in patients with atrial fibrillation (AF) is limited. Therefore, this study aimed to compare the effects of BP-lowering drugs in pat
Externí odkaz:
https://doaj.org/article/81c16b9b28014d97b18da4c01305443f
Publikováno v:
PLoS ONE, Vol 16, Iss 11 (2021)
Objectives This post-trial data linkage analysis was to utilize the data of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants linked with their Medicare data to examine the risk of hospitalized and non-
Externí odkaz:
https://doaj.org/article/9b84767191ce4888acc164888e10721e
Publikováno v:
International Journal of Hypertension, Vol 2021 (2021)
Background. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) ended in 2002, but it is important to study its long-term outcomes during the posttrial period by incorporating posttrial antihypertensive medication use
Externí odkaz:
https://doaj.org/article/afdbfd634afe44c7b728290306416d00
Autor:
Andi Shahu, Jeph Herrin, Sanket S. Dhruva, Nihar R. Desai, Barry R. Davis, Harlan M. Krumholz, Erica S. Spatz
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 15 (2019)
Background Observational studies demonstrate that communities of low socioeconomic status have higher blood pressure and worse cardiovascular outcomes. Yet, whether the clinical outcomes resulting from antihypertensive therapy vary by socioeconomic c
Externí odkaz:
https://doaj.org/article/d9061a722a0b4ce7a882ef78d48e59a6
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 8 (2019)
Background Hypertension is a known risk factor for heart failure (HF), possibly via the mechanism of cardiac remodeling and left ventricular hypertrophy (LVH). We studied the extent to which blood pressure (BP) change and evolving LVH contribute to t
Externí odkaz:
https://doaj.org/article/34c98891addb46f3a877860d5006e642
Autor:
Kunal N Karmali, Donald M Lloyd-Jones, Joep van der Leeuw, David C Goff, Salim Yusuf, Alberto Zanchetti, Paul Glasziou, Rodney Jackson, Mark Woodward, Anthony Rodgers, Bruce C Neal, Eivind Berge, Koon Teo, Barry R Davis, John Chalmers, Carl Pepine, Kazem Rahimi, Johan Sundström, Blood Pressure Lowering Treatment Trialists’ Collaboration
Publikováno v:
PLoS Medicine, Vol 15, Iss 3, p e1002538 (2018)
BACKGROUND:Clinical practice guidelines have traditionally recommended blood pressure treatment based primarily on blood pressure thresholds. In contrast, using predicted cardiovascular risk has been advocated as a more effective strategy to guide tr
Externí odkaz:
https://doaj.org/article/2157a9103dc4487b85df108871739067
Autor:
Ferrán Catalá-López, Diego Macías Saint-Gerons, Diana González-Bermejo, Giuseppe M Rosano, Barry R Davis, Manuel Ridao, Abel Zaragoza, Dolores Montero-Corominas, Aurelio Tobías, César de la Fuente-Honrubia, Rafael Tabarés-Seisdedos, Brian Hutton
Publikováno v:
PLoS Medicine, Vol 13, Iss 3, p e1001971 (2016)
BackgroundMedications aimed at inhibiting the renin-angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. W
Externí odkaz:
https://doaj.org/article/cb0fbec97c0c4a97b964cd1d790684be
Autor:
Robert Barrington, Gary Williamson, Richard N. Bennett, Barry D. Davis, Jennifer S. Brodbelt, Paul A. Kroon
Publikováno v:
Journal of Functional Foods, Vol 1, Iss 1, Pp 74-87 (2009)
Flavonoids are biologically active compounds in food with potential health effects. We have used the CaCo-2 cell monolayer model to study the absorption and metabolism of two flavonols, a class of flavonoids, specifically kaempferol and galangin. Met
Externí odkaz:
https://doaj.org/article/d8a680315bd9459ba22627e83c96b2b2